What’s the difference between Trelegy 100 and Trelegy 200?
Trelegy is an inhaled controller for chronic obstructive pulmonary disease (COPD) and is dosed by its strength, which changes the amount of the inhaled corticosteroid (fluticasone furoate) per puff. The two common strengths are:
- Trelegy 100: lower fluticasone furoate dose per actuation.
- Trelegy 200: higher fluticasone furoate dose per actuation.
The rest of the device’s role stays the same: Trelegy combines three medicines in one inhaler—an inhaled steroid (to reduce inflammation), a long-acting muscarinic antagonist (LAMA) (to relax airways), and a long-acting beta-agonist (LABA) (to keep airways open). The “100 vs 200” labeling refers to the steroid dose level, not a switch in the type of inhaler.
When would a clinician choose Trelegy 200 instead of Trelegy 100?
Clinicians typically consider a higher-strength inhaled steroid dose (Trelegy 200) for people whose COPD is not adequately controlled on a lower steroid strength, or who have features that make the inflammation component more important. In practice, the “step up” to Trelegy 200 often happens when symptoms or exacerbations continue despite prior treatment.
Your prescriber should decide based on:
- Symptom control (breathlessness, daily limitations)
- Exacerbation history (how often flare-ups occur)
- Current inhaler regimen and response
- Side-effect risk (especially steroid-related effects)
Does Trelegy 200 have more side effects than Trelegy 100?
Because Trelegy 200 contains more fluticasone per dose, steroid-related adverse effects can be more likely at the higher strength, such as:
- Oral thrush (candidiasis)
- Hoarseness or throat irritation
The general mitigation steps are the same for either strength: use the inhaler exactly as prescribed and rinse/gargle after inhaled steroid use (and spit), to reduce thrush risk.
Systemic steroid effects are also a concern with higher doses, though the inhaled route generally limits systemic exposure compared with tablets. If you have a history of infections or you’re prone to thrush, that’s a point to discuss with your clinician when deciding between strengths.
How are dosing schedules the same (and how can they differ)?
Trelegy products are once-daily inhalers. The practical difference between 100 and 200 is the strength per puff, not the dosing frequency. If you’re switching, the key is that the inhaler prescription should match the correct strength so you get the intended steroid exposure.
If you ever double up by mistake (for example, switching devices without updating your dose), that can increase side-effect risk.
Can patients switch from 100 to 200 on their own?
Switching strengths should be guided by your prescriber. Going from 100 to 200 changes the steroid exposure, and that should align with a treatment plan based on control and exacerbation risk. If you’re considering the change because symptoms aren’t improving, it’s usually better to contact your clinician rather than self-adjust.
What about patents, pricing, and availability differences?
Product strength can affect coverage tiers, copays, and pharmacy pricing, even when the inhaler is otherwise the same class. If you’re trying to control cost or check alternatives, DrugPatentWatch.com can help you track branded and related product timelines and filings that may affect market access. You can search Trelegy-related entries here: DrugPatentWatch.com.
What should you watch for after switching?
After changing strength (or starting either strength), watch for:
- Thrush symptoms (white patches in mouth, soreness)
- Hoarseness or persistent throat irritation
- Worsening breathing (which may signal incorrect inhaler technique, need for reassessment, or that the regimen isn’t sufficient)
If symptoms worsen soon after a change, contact your clinician promptly.
---
If you tell me whether you’re using Trelegy for COPD or asthma, and what your current prescription says (the exact “100” or “200” strength and how many puffs per day), I can tailor the comparison to the likely reason for choosing that strength.
Sources